|
Ground-breaking regional
anesthesia system to become
available in Saudi Arabia,
the UAE and Bahrain
(Dubai, UAE) -
UK-based Medovate,
a medical device development
company, has today announced
an agreement with AKSIA
Healthcare FZC to distribute
its SAFIRA™ (SAFer Injection
for Regional Anesthesia)
product range in Saudi
Arabia, the UAE and Bahrain.
SAFIRA™ is a
revolutionary Class II
medical device system which
is transforming regional
anesthesia around the world
by making it a one-person
procedure and incorporating
a built-in safety system to
automatically limit
injection pressure.
Following regulatory
approvals, SAFIRA™ will
become available through
AKSIA Healthcare FZC in
these three key Middle East
markets.
Developed in
collaboration with
clinicians from the National
Health Service (NHS) in the
UK, the award-winning system
puts full control of the
injection in the hands of
the anesthesiologist,
freeing up the previously
required assistant to carry
out other tasks. The system
also helps to improve
patient safety by reducing
the risk of nerve damage as
it automatically limits
injection pressure to less
than 20 psi.
Speaking
about their partnership with
AKSIA Healthcare FZC Chris
Rogers, Sales and Marketing
Director, at Medovate, said:
“We are delighted to be
working with Aksia
Healthcare FZC as we now
work towards launching
SAFIRA in these key markets.
This agreement will allow
patients and clinicians in
both governmental and
private facilities to
benefit from the value that
SAFIRA brings to safer
regional anesthesia.”
Ahmed Sallam, Managing
Director of AKSIA Healthcare
FZC, added: “We are pleased
to enter this partnership
with Medovate to distribute
SAFIRA™ across the United
Arab Emirates, Saudi Arabia
and Bahrain. There is a real
need for a system like this,
not only to help improve
patient safety but also to
have a huge impact on the
way regional anesthesia is
carried out by
anesthesiologists.”
SAFIRA™ was demonstrated
live at Arab Health 2022 by
one of its inventors, Dr
Emad Fawzy, a Consultant
Anesthesiologist, at the
flagship Sheikh Khalifa
Medical City in Abu Dhabi.
Dr Fawzy added: “I
am delighted that this
pioneering UK-developed
medical system will soon be
available to use across more
Middle East states. The
system has already been used
by clinicians across the
world and feedback has been
overwhelmingly positive. We
are expecting a large demand
for it from Middle Eastern
clinicians as it has a huge
impact on patient safety.”
SAFIRA™ has the potential to
make a significant impact by
making injection during
regional anaesthesia safer,
reducing the risk of nerve
injury from injection at
high pressures. It won the
United Kingdom HSJ ‘Patient
Safety Innovation of the
Year’ award in 2021.
Recent publications,
including a joint statement
by the American Society of
Regional Anesthesia and Pain
Management (ASRA) and the
European Society of Regional
Anesthesia and Pain Therapy
(ESRA), have recommended
regional anesthesia be
considered whenever surgery
is planned for a suspected
or confirmed COVID-19
patient. This is because it
preserves respiratory
function and avoids
aerosolization and the
potential for transmission
of COVID-19 compared to
general anesthesia.
In Saudi Arabia in
2020 there were just under
3,500 practicing
anesthesiologists and
research conducted in 2012
showed 88% of
anesthesiologists in Saudi
Arabia were practicing
regional anesthesia on a
daily basis.
PRINT
THIS ARTICLE
|